Panel backs lighter Avandia restrictions, but drug's rehabilitation unlikely
This article was originally published in Scrip
While a US FDA advisory committee on 6 June was not ready to completely vindicate GlaxoSmithKline's RECORD study of the firm's once-blockbuster, now restricted, Type II diabetes drug Avandia (rosiglitazone), a majority of the panelists said they were now more comfortable with the results – although most still considering the trial flawed – and voted to loosen the restrictive program on the medicine, whose scripts have fallen by 99% since the product's 2006 glory days.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.